AEON Biopharma (NASDAQ:AEON) Trading Up 5.9% – Time to Buy?

AEON Biopharma, Inc. (NASDAQ:AEON) shares were up 5.9% during trading on Tuesday . The stock traded as high as $1.10 and last traded at $1.08. Approximately 141,676 shares were traded during trading, a decline of 87% from the average daily volume of 1,124,368 shares. The stock had previously closed at $1.02.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on AEON shares. Zacks Research raised AEON Biopharma to a “hold” rating in a research note on Tuesday, November 18th. HC Wainwright raised shares of AEON Biopharma to a “strong-buy” rating in a research report on Friday, November 14th. Finally, Aegis reissued a “buy” rating on shares of AEON Biopharma in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy”.

AEON Biopharma Stock Performance

The stock’s 50-day simple moving average is $0.90 and its 200 day simple moving average is $0.84. The company has a market capitalization of $12.79 million, a PE ratio of 6.00 and a beta of 0.75.

About AEON Biopharma

AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical‐stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.

Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.